Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market

Executive Summary

CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.

You may also be interested in...



HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response

HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.

10 Things For Pfizer's New CEO To Worry About

Albert Bourla will face opportunities and potential pitfalls.

To Lower Drug Prices, Look At Generic Industry Health Rather Than FDA, Woodcock Says

US FDA can encourage and increase competition, but cannot force generic companies to enter markets deemed unprofitable, CDER director says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel